Bone Marrow Transplantation - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Bone Marrow Transplantation - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Bone Marrow Transplantation - Pipeline Review, H1 2015’, provides an overview of the Bone Marrow Transplantation’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bone Marrow Transplantation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Bone Marrow Transplantation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bone Marrow Transplantation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplantation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bone Marrow Transplantation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Bone Marrow Transplantation Overview 8
Therapeutics Development 9
Pipeline Products for Bone Marrow Transplantation - Overview 9
Pipeline Products for Bone Marrow Transplantation - Comparative Analysis 10
Bone Marrow Transplantation - Therapeutics under Development by Companies 11
Bone Marrow Transplantation - Therapeutics under Investigation by Universities/Institutes 12
Bone Marrow Transplantation - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Bone Marrow Transplantation - Products under Development by Companies 16
Bone Marrow Transplantation - Products under Investigation by Universities/Institutes 17
Bone Marrow Transplantation - Companies Involved in Therapeutics Development 18
Anchor Therapeutics, Inc. 18
Boryung Pharmaceutical Co., Ltd. 19
Cantex Pharmaceuticals, Inc. 20
Cellerant Therapeutics, Inc. 21
Cleveland BioLabs, Inc. 22
Compugen Ltd. 23
Mesoblast Limited 24
Pluristem Therapeutics Inc. 25
Proteonomix, Inc. 26
Spectrum Pharmaceuticals, Inc. 27
Taiga Biotechnologies, Inc. 28
Wellstat Therapeutics Corporation 29
Bone Marrow Transplantation - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
(filgrastim + plerixafor) - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ATI-2341 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
BR-05001 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
CBLB-612 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Cell Therapy for Bone Marrow Transplantation - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CGEN-15001 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
melphalan - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
MPC-CBE - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PGX-100 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
PLX-RAD - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
PN-951 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Protein for Bone Marrow Transplantation - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
romyelocel-L - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecules to Inhibit Perforin for Bone Marrow Transplantation - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Bone Marrow Transplantation - Recent Pipeline Updates 60
Bone Marrow Transplantation - Dormant Projects 70
Bone Marrow Transplantation - Discontinued Products 71
Bone Marrow Transplantation - Product Development Milestones 72
Featured News & Press Releases 72
Mar 03, 2015: Pluristem and Hadassah Medical Center Announce Significant Data Showing PLX-R18 Cells Improve Bone Marrow Transplantation 72
Dec 04, 2014: Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes 73
Nov 13, 2014: Cell Source's Megadose Drug Combination Receives Regulatory Approval in Italy to Commence Human Clinical Trials 74
Oct 27, 2014: Case Western Reserve University to Study Pluristem’s PLX-RAD Cells in Umbilical Cord Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases 74
Apr 23, 2014: Spectrum Pharmaceuticals’ Pivotal Trial of Captisol-Enabled Melphalan Meets Primary Endpoint 75
May 07, 2013: Pluristem Develops PLX-RAD Cells For Use In Hematology 76
Sep 05, 2012: Pluristem Therapeutics Announces Successfully Treatment Of Third Critically Ill Patient With PLX Cells Under Compassionate Use 77
May 09, 2012: Pluristem's PLX Cells Saves Life Of Child After Bone Marrow Transplantation Failure 78
Feb 01, 2012: Ligand Presents Successful Phase II Results For Captisol-Enabled, Propylene Glycol-Free Melphalan At BMT Tandem Meetings 79
Jul 07, 2011: Mesoblast Receives FDA Clearance For Phase III Bone Marrow Transplant Trial 80
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 82
Disclaimer 83

List of Tables

Number of Products under Development for Bone Marrow Transplantation, H1 2015 9
Number of Products under Development for Bone Marrow Transplantation - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Bone Marrow Transplantation - Pipeline by Anchor Therapeutics, Inc., H1 2015 18
Bone Marrow Transplantation - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2015 19
Bone Marrow Transplantation - Pipeline by Cantex Pharmaceuticals, Inc., H1 2015 20
Bone Marrow Transplantation - Pipeline by Cellerant Therapeutics, Inc., H1 2015 21
Bone Marrow Transplantation - Pipeline by Cleveland BioLabs, Inc., H1 2015 22
Bone Marrow Transplantation - Pipeline by Compugen Ltd., H1 2015 23
Bone Marrow Transplantation - Pipeline by Mesoblast Limited, H1 2015 24
Bone Marrow Transplantation - Pipeline by Pluristem Therapeutics Inc., H1 2015 25
Bone Marrow Transplantation - Pipeline by Proteonomix, Inc., H1 2015 26
Bone Marrow Transplantation - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 27
Bone Marrow Transplantation - Pipeline by Taiga Biotechnologies, Inc., H1 2015 28
Bone Marrow Transplantation - Pipeline by Wellstat Therapeutics Corporation, H1 2015 29
Assessment by Monotherapy Products, H1 2015 30
Assessment by Combination Products, H1 2015 31
Number of Products by Stage and Target, H1 2015 33
Number of Products by Stage and Mechanism of Action, H1 2015 35
Number of Products by Stage and Route of Administration, H1 2015 37
Number of Products by Stage and Molecule Type, H1 2015 39
Bone Marrow Transplantation Therapeutics - Recent Pipeline Updates, H1 2015 60
Bone Marrow Transplantation - Dormant Projects, H1 2015 70
Bone Marrow Transplantation - Discontinued Products, H1 2015 71